Business
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of MedicineU.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for atacicept with Prescription Drug User Fee Act (PDUFA) date of July 7, 2026; potential commercial launch of atacicept expected in mid-2026Strong balance sheet bolstered by equity and debt financings
About this update from Vera Therapeutics, Inc.
[{"type":"image","alt":"Vera Therapeutics","displaySize":"","headline":null,"caption":"Vera Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/72a8e9e8ecc86f0d9732b38c0cd327c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6..aCv7B4Q_6wAcqlLyx_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/72a8e9e8ecc86f0d9732b38c0cd327c5","width":300,"height":300}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of Medicine","length":195,"tagName":"p"}]},{"val":[{"type":"text","content":"U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for atacicept with Prescription Drug User Fee Act (PDUFA) date of July 7, 2026; potential commercial launch of atacicept expected in mid-2026","length":244,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong balance sheet bolstered by equity and debt financings in 2025 expected to be sufficient to fund company beyond atacicept approval and U.S. commercial launch","length":163,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":602,"olType":false},{"type":"text","content":"BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the full year ended December 31, 2025.","length":357,"tagName":"p"},{"type":"text","content":"“In 2025, Vera Therapeutics delivered on several key milestones as we advanced atacicept toward potential FDA approval and commercialization,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. “The BLA has been granted priority review and we expect to be commercially prepared to successfully launch atacicept in IgAN in mid-2026 if approved. Our commercial team brings decades of experience launching innovative therapies and is eager to bring this potentially disease-modifying therapy to patients with IgAN and other autoi...